Maccura Biotechnology Co.Ltd

Shenzhen Stock Exchange 300463.SZ

Maccura Biotechnology Co.Ltd EBIT Margin for the year ending December 31, 2023: 11.70%

Maccura Biotechnology Co.Ltd EBIT Margin is 11.70% for the year ending December 31, 2023, a -48.77% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Maccura Biotechnology Co.Ltd EBIT Margin for the year ending December 31, 2022 was 22.85%, a -26.85% change year over year.
Maccura Biotechnology Co.Ltd EBIT Margin for the year ending December 31, 2021 was 31.23%, a 11.83% change year over year.
Maccura Biotechnology Co.Ltd EBIT Margin for the year ending December 31, 2020 was 27.93%, a 18.90% change year over year.
Maccura Biotechnology Co.Ltd EBIT Margin for the year ending December 31, 2019 was 23.49%, a -1.50% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

Shenzhen Stock Exchange: 300463.SZ

Maccura Biotechnology Co.Ltd

CEO	Mr. Wu Mingjian
IPO Date	May 28, 2015
Location	China
Headquarters	Hi-tech Zone
Employees	3,362
Sector	Healthcare
Industries Biotechnology 3D Printing Chemicals & Advanced Materials Cleaning Supplies Medical Instruments Personal Care Pharmaceuticals Plastics

Description

Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of IVD products and related services in China and internationally. The company offers immunoassay products, such as chemiluminescence analyzers and reagents; clinical chemistry reagents for hepatic function, glycometabolism, iron and other, renal function, coagulation, special protein, cardiac, and lipids; and clinical laboratory products, such as automatic hematology, and automatic and semi-automatic coagulation analyzers. It also provides SARS-COV-2(COVID-19) products that includes nucleic acid detection kit and other products; glucometers; POCT products, such as fluorescence immunoassay analyzers, as well as colloidal gold kits; molecular diagnosis products, such as PCR kit; and pathology products. The company was incorporated in 1994 and is based in Chengdu, China.

Key trends

Past 5 years